Nuvelo Announces Preclinical Data For NU206 Demonstrating Potent Therapeutic Activity In Oral Mucositis Models
Apr 17th 2008Drug InformationGastroIntestinal / Gastroentorology
Nuvelo, Inc. (Nasdaq: NUVO) announced preclinical data demonstrating the mechanism of action and the potent therapeutic activity of NU206 (R-spondin1) in chemotherapy or radiation-induced oral mucositis models. The data were presented in a poster session yesterday at the 2008 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
